Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Humana (HUM)

NYSE: HUM · Managed Health Care · Louisville, KY

Our rating: Cautious

Cautious reaffirmed at $423.22, high conviction, November 9, 2026.

Breaks if: The Cautious view is wrong if Humana reports a net margin above 2.5% — consistent with a genuine normalization in its medical cost ratio — in two consecutive quarterly filings within the next 12 months, accompanied by free cash flow recovering above $1.5B on a trailing-twelve-month basis. A sustained move above $550 within the next twelve months while margins remain at current levels would also suggest the market is pricing a recovery path the reported figures do not yet support.

Key figures

Market value$46.8B
Revenue, last 12 months$154.2B
Net income, last 12 months$1.2B
Free cash flow, last 12 months$3.1B
Price to earnings37.6×
Free cash flow yield6.7%
Dividend yield0.9%
Operating margin1.5%
Return on equity6.7%
Beta to the S&P 5000.39
Volatility, annualized45.6%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$41.2B26.1%$1.33$2.0B
June 30, 2026$40.9B26.2%$5.73$1.8B
March 31, 2026$39.6B23.5%$9.83$1.1B
December 31, 2025$32.5B11.3%$-6.59−$1.9B
September 30, 2025$32.6B11.1%$1.62$836M
June 30, 2025$32.4B9.6%$4.51$1.2B
March 31, 2025$32.1B8.4%$10.30$236M
December 31, 2024$29.2B10.4%$-5.74−$682M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

13 ledger entries and 58 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.